Considerations for the clinical use of contrast agents for cellular MRI in regenerative medicine

Contrast Media and Molecular Imaging

Volumn 8, Issue 6, 2013, Pages 439-455

  Modo, Michel ^a   Kolosnjaj Tabi, Jelena ^b   Nicholls, Francesca ^a,c   Ling, Wen ^a   Wilhelm, Claire ^b   Debarge, Olivier ^d   Gazeau, Florence ^b   Clement, Olivier ^b  

^a MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CRDT EA 3312   (France)

Author keywords

Advanced Therapy Medicinal Products; Cell Therapy; Cellular MRI; Clinical translation; Contrast agent; Image Guidance; MRI; Regenerative Medicine; Regulatory pathway; Theranostics; Therapeutic Monitoring; Tissue Engineering; Toxicity

Indexed keywords

CONTRAST MEDIUM;

ARTICLE; CELL LABELING; CELL TRACKING; DRUG EFFICACY; DRUG SAFETY; EUROPEAN UNION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REGENERATIVE MEDICINE;

ADVANCED THERAPY MEDICINAL PRODUCTS; CELL THERAPY; CELLULAR MRI; CLINICAL TRANSLATION; CONTRAST AGENT; IMAGE GUIDANCE; MRI; REGENERATIVE MEDICINE; REGULATORY PATHWAY; THERANOSTICS; THERAPEUTIC MONITORING; TISSUE ENGINEERING; TOXICITY;

ANIMALS; CELL MOVEMENT; CELL TRACKING; HUMANS; MAGNETIC RESONANCE IMAGING; REGENERATIVE MEDICINE; STEM CELLS;

EID: 84890941178     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1547     Document Type: Article

References (94)

1. Burger SR. Current regulatory issues in cell and tissue therapy. Cytotherapy 2003; 5(4):289-298.
2. European Council. On the community code relating to medicinal products for human use. 2001/83/EC. Off J L: EU 2004; 67-128.
3. Soto-Gutierrez A, Yagi H, Uygun BE, Navarro-Alvarez N, Uygun K, Kobayashi N, Yang YG, Yarmush ML. Cell delivery: from cell transplantation to organ engineering. Cell Transplantation 2010; 19(6):655-665.
4. Mathews DJ, Sugarman J, Bok H, Blass DM, Coyle JT, Duggan P, Finkel J, Greely HT, Hillis A, Hoke A, Johnson R, Johnston M, Kahn J, Kerr D, Kurtzberg J, Liao SM, McDonald JW, McKhann G, Nelson KB, Rao M, Regenberg A, Siegel AW, Smith K, Solter D, Song H, Vescovi A, Young W, Gearhart JD, Faden R. Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology 2008; 71(4):288-293.
5. Shim W, Mehta A, Wong P, Chua T, Koh TH. Critical path in cardiac stem cell therapy: an update on cell delivery. Cytotherapy 2013; 15(4):399-415.
6. Misra V, Ritchie MM, Stone LL, Low WC, Janardhan V. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy. Neurology 2012; 79(13 suppl 1):S207-212.
7. Fong CY, Gauthaman K, Bongso A. Teratomas from pluripotent stem cells: a clinical hurdle. Journal of Cellular Biochemistry 2010; 111(4):769-781.
8. Modo M Noninvasive imaging of transplanted cells. Current Opinion in Organ Transplantation 2008; 13(6):654-658.
9. Modo M, Hoehn M, Bulte JW. Cellular MR imaging. Mol Imag 2005; 4(3):143-164.
10. Zhang Y, Ruel M, Beanlands RS, de Kemp RA, Suuronen EJ, DaSilva JN. Tracking stem cell therapy in the myocardium: applications of positron emission tomography. Current Pharm Des 2008; 14(36):3835-3853.
11. Chin BB, Nakamoto Y, Bulte JW, Pittenger MF, Wahl R, Kraitchman DL. 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nuclear Med Commun 2003; 24(11):1149-1154.
12. Gyongyosi M, Blanco J, Marian T, Tron L, Petnehazy O, Petrasi Z, Hemetsberger R, Rodriguez J, Font G, Pavo IJ, Kertesz I, Balkay L, Pavo N, Posa A, Emri M, Galuska L, Kraitchman DL, Wojta J, Huber K, Glogar D. Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. Circul Cardiovas Imag 2008; 1(2):94-103.
13. Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of alpha-synuclein neuropathology required and feasible? Brain Research Reviews 2010; 65(1):28-55.
14. Nam SY, Ricles LM, Suggs LJ, Emelianov SY. In vivo ultrasound and photoacoustic monitoring of mesenchymal stem cells labeled with gold nanotracers. PloS One 2012; 7(5):e37267.
15. Kim J, Arifin DR, Muja N, Kim T, Gilad AA, Kim H, Arepally A, Hyeon T, Bulte JW. Multifunctional capsule-in-capsules for immunoprotection and trimodal imaging. Angewandte Chemie 2011; 50(10):2317-2321.
16. Puppi J, Modo M. Use of magnetic resonance imaging contrast agents to detect transplanted liver cells. Top Magn Reson Imag 2009; 20(2):113-120.
17. Bulte JW. In vivo MRI cell tracking: clinical studies. American Journal of Roentgenology 2009; 193(2):314-325.
18. PRWeb. The first patient treated using Celsense MRI cell tracking technology, 2013. Available from: http://www.prweb.com/releases/2013/4/prweb10616006.htm.
19. Almeida JP, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine 2011; 6(5):815-835.
20. European Council. On advanced therapy medicinal products and amending directive 2001/83/CE and regulation (EC) no. 726/2004. Volume 1394/2007/EC. Off J EU 2007; 121-137.
21. Farrugia A. When do tissues and cells become products? Regulatory oversight of emerging biological therapies. Cell and Tissue Banking 2006; 7(4):325-335.
22. Arifin DR, Long CM, Gilad AA, Alric C, Roux S, Tillement O, Link TW, Arepally A, Bulte JW. Trimodal gadolinium-gold microcapsules containing pancreatic islet cells restore normoglycemia in diabetic mice and can be tracked by using US, CT, and positive-contrast MR imaging. Radiology 2011; 260(3):790-798.
23. Al Faraj A, Luciani N, Kolosnjaj-Tabi J, Mattar E, Clement O, Wilhelm C, Gazeau F. Real-time high-resolution magnetic resonance tracking of macrophage subpopulations in a murine inflammation model: a pilot study with a commercially available cryogenic probe. Contrast Media Mol Imag 2013; 8(2):193-203.
24. Granot D, Scheinost D, Markakis EA, Papademetris X, Shapiro EM. Serial monitoring of endogenous neuroblast migration by cellular MRI. NeuroImage 2011; 57(3):817-824.
25. Riegler J, Wells JA, Kyrtatos PG, Price AN, Pankhurst QA, Lythgoe MF. Targeted magnetic delivery and tracking of cells using a magnetic resonance imaging system. Biomaterials 2010; 31(20):5366-5371.
26. Chaudeurge A, Wilhelm C, Chen-Tournoux A, Farahmand P, Bellamy V, Autret G, Menager C, Hagege A, Larghero J, Gazeau F, Clement O, Menasche P. Can magnetic targeting of magnetically labeled circulating cells optimize intramyocardial cell retention? Cell Transplantation 2012; 21(4):679-691.
27. Ilic N, Savic S, Siegel E, Atkinson K, Tasic L. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II - a method of software documentary analysis. Stem Cells Translat Med 2012; 1(12):909-920.
28. Ilic N, Savic S, Siegel E, Atkinson K, Tasic L. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part I - a method of manual documentary analysis. Stem Cells Translat Med 2012; 1(12):898-908.
29. European Council. On setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissue and cells. Volume 2004/23/EC. Off J EU 2004; L: 48-58.
30. Salzberg M, Muller E. Quality requirements in clinical studies: a necessary burden? Swiss Medical Weekly 2003; 133(31-32):429-432.
31. Williams DJ, Thomas RJ, Hourd PC, Chandra A, Ratcliffe E, Liu Y, Rayment EA, Archer JR. Precision manufacturing for clinical-quality regenerative medicines. Philosophical Trans Ser A, Math Phys Eng Sci 2012; 370(1973):3924-3949.
32. Au P, Hursh DA, Lim A, Moos MC, Jr, Oh SS, Schneider BS, Witten CM. FDA oversight of cell therapy clinical trials. Science Translat Med 2012; 4(149):149fs131.
33. Sciacovelli L, Plebani M. The IFCC Working Group on laboratory errors and patient safety. Clinica Chimica Acta 2009; 404(1):79-85.
34. Carter JF, Fry B. Ensuring the reliability of stable isotope ratio data-beyond the principle of identical treatment. Analytical and Bioanalytical Chemistry Mar. 2013; 405(9):2799-814.
35. European Medicines Agency. Procedure for European Union Guidelines and Related Documents within the Pharmaceutical Legislative Framework. EMEA: London, 2009.
36. UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases. Handbook: Good Laboratory Practice (GLP). World Health Organization: Geneva, 2001.
37. UNICEF/UNDP/World Bank/WHO. Special Programme for Research and Training in Tropical Diseases. Good Clinical Laboratory Practice (GCLP). World Health Organization: Geneva, 2009.
38. Prathalingam N, Ferguson L, Young L, Lietz G, Oldershaw R, Healy L, Craig A, Lister H, Binaykia R, Sheth R, Murdoch A, Herbert M. Production and validation of a good manufacturing practice grade human fibroblast line for supporting human embryonic stem cell derivation and culture. Stem Cell Res Ther 2012; 3(2):12.
39. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Evelhoch J, Hargreaves R, Robertson B, Iyengar S, Tauscher J, Bleakman D, Borsook D. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Drug Discovery Today 2011; 16(13-14):583-593.
40. Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Evelhoch J, Hargreaves R, Robertson B, Iyengar S, Tauscher J, Bleakman D, Borsook D. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discovery Today 2011; 16(15-16):671-682.
41. Regenberg A, Mathews DJ, Blass DM, Bok H, Coyle JT, Duggan P, Faden R, Finkel J, Gearhart JD, Hillis A, Hoke A, Johnson R, Johnston M, Kahn J, Kerr D, King P, Kurtzberg J, Liao SM, McDonald JW, McKhann G, Nelson KB, Rao M, Siegel AW, Smith K, Solter D, Song H, Sugarman J, Vescovi A, Young W, Greely HT, Traystman RJ. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cerebral Blood Flow Metab 2009; 29(1):1-9.
42. Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Safety 1996; 15(1):1-7.
43. Lis Y, Roberts MH, Kamble S, Guo JJ, Raisch DW. Comparisons of food and drug administration and European medicines agency risk management implementation for recent pharmaceutical approvals: report of the international society for pharmacoeconomics and outcomes research risk benefit management working group. Value Health 2012; 15(8):1108-1118.
44. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value in Health 2010; 13(5):657-666.
45. Lazo-Langner A, Rodger MA, Barrowman NJ, Ramsay T, Wells PS, Coyle DA. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis. BMC Medical Research Methodology 2012; 12:3.
46. Rodriguez-Porcel M, Kronenberg MW, Henry TD, Traverse JH, Pepine CJ, Ellis SG, Willerson JT, Moye LA, Simari RD. Cell tracking and the development of cell-based therapies: a view from the Cardiovascular Cell Therapy Research Network. JACC Cardiovasc Imag 2012; 5(5):559-565.
47. Kim YJ, Huh YM, Choe KO, Choi BW, Choi EJ, Jang Y, Lee JM, Suh JS. In vivo magnetic resonance imaging of injected mesenchymal stem cells in rat myocardial infarction; simultaneous cell tracking and left ventricular function measurement. Int J Cardiovasc Imag 2009; 25 suppl 1:99-109.
48. Laurent S, Boutry S, Mahieu I, Vander Elst L, Muller RN. Iron oxide based MR contrast agents: from chemistry to cell labeling. Current Medicinal Chemistry 2009; 16(35):4712-4727.
49. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, Klaessig F, Castranova V, Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials 2009; 8(7):543-557.
50. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008; 105(38):14265-14270.
51. Levy M, Wilhelm C, Devaud M, Levitz P, Gazeau F. How cellular processing of superparamagnetic nanoparticles affects their magnetic behavior and NMR relaxivity. Contrast Media Mol Imag 2012; 7(4):373-383.
52. Soenen SJ, De Smedt SC, Braeckmans K. Limitations and caveats of magnetic cell labeling using transfection agent complexed iron oxide nanoparticles. Contrast Media Mol Imag 2012; 7(2):140-152.
53. Terreno E, Geninatti Crich S, Belfiore S, Biancone L, Cabella C, Esposito G, Manazza AD, Aime S. Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons. Magnetic Resonance in Medicine 2006; 55(3):491-497.
54. Delli Castelli D, Terreno E, Aime S. Yb(III)-HPDO3A: a dual pH- and temperature-responsive CEST agent. Angewandte Chemie 2011; 50(8):1798-1800.
55. Laskar A, Ghosh M, Khattak SI, Li W, Yuan XM. Degradation of superparamagnetic iron oxide nanoparticle-induced ferritin by lysosomal cathepsins and related immune response. Nanomedicine 2012; 7(5):705-717.
56. Luciani N, Wilhelm C, Gazeau F. The role of cell-released microvesicles in the intercellular transfer of magnetic nanoparticles in the monocyte/macrophage system. Biomaterials 2010; 31(27):7061-7069.
57. Silva AK, Wilhelm C, Kolosnjaj-Tabi J, Luciani N, Gazeau F. Cellular transfer of magnetic nanoparticles via cell microvesicles: impact on cell tracking by magnetic resonance imaging. Pharmaceutical Research 2012; 29(5):1392-1403.
58. Kedziorek DA, Muja N, Walczak P, Ruiz-Cabello J, Gilad AA, Jie CC, Bulte JW. Gene expression profiling reveals early cellular responses to intracellular magnetic labeling with superparamagnetic iron oxide nanoparticles. Magnetic Resonance in Medicine 2010; 63(4):1031-1043.
59. Walczak P, Kedziorek DA, Gilad AA, Barnett BP, Bulte JW. Applicability and limitations of MR tracking of neural stem cells with asymmetric cell division and rapid turnover: the case of the shiverer dysmyelinated mouse brain. Magnetic Resonance in Medicine 2007; 58(2):261-269.
60. Ribot EJ, Foster PJ. In vivo MRI discrimination between live and lysed iron-labelled cells using balanced steady state free precession. Europ Radiol 2012; 22(9):2027-2034.
61. Guenoun J, Ruggiero A, Doeswijk G, Janssens RC, Koning GA, Kotek G, Krestin GP, Bernsen MR. In vivo quantitative assessment of cell viability of gadolinium or iron-labeled cells using MRI and bioluminescence imaging. Contrast Media Mol Imag 2013; 8(2):165-174.
62. Puppi J, Mitry RR, Modo M, Dhawan A, Raja K, Hughes RD. Use of a clinically approved iron oxide MRI contrast agent to label human hepatocytes. Cell Transplantation 2011; 20(6):963-975.
63. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature Biotechnology 2005; 23(11):1407-1413.
64. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. New Engl J Med 2006; 355(22):2376-2378.
65. Levy M, Luciani N, Alloyeau D, Elgrabli D, Deveaux V, Pechoux C, Chat S, Wang G, Vats N, Gendron F, Factor C, Lotersztajn S, Luciani A, Wilhelm C, Gazeau F. Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials 2011; 32(16):3988-3999.
66. Modo M, Beech JS, Meade TJ, Williams SC, Price J. A chronic 1 year assessment of MRI contrast agent-labelled neural stem cell transplants in stroke. NeuroImage 2009; 47(suppl 2):T133-142.
67. Berman SC, Galpoththawela C, Gilad AA, Bulte JW, Walczak P. Long-term MR cell tracking of neural stem cells grafted in immunocompetent versus immunodeficient mice reveals distinct differences in contrast between live and dead cells. Magnetic Resonance in Medicine 2011; 65(2):564-574.
68. Obenaus A, Dilmac N, Tone B, Tian HR, Hartman R, Digicaylioglu M, Snyder EY, Ashwal S. Long-term magnetic resonance imaging of stem cells in neonatal ischemic injury. Annals of Neurology 2011; 69(2):282-291.
69. Taylor A, Wilson KM, Murray P, Fernig DG, Levy R. Long-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet? Chemical Society Reviews 2012; 41(7):2707-2717.
70. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imag 2009; 30(6):1259-1267.
71. Bible E, Dell'Acqua F, Solanky B, Balducci A, Crapo PM, Badylak SF, Ahrens ET, Modo M. Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (19)F- and diffusion-MRI. Biomaterials 2012; 33(10):2858-2871.
72. Puppi J, Modo M, Dhawan A, Lehec SC, Mitry RR, Hughes RD. Ex vivo magnetic resonance imaging of transplanted hepatocytes in a rat model of acute liver failure. Cell Transplantation. In Press (DOI: 10.3727/09638913X663596)
73. Loewendorf A, Csete M. Concise Review: Immunologic lessons from solid organ transplantation for stem cell-based therapies. Stem Cells Transl Med 2013; 2(2):136-142.
74. de Chickera S, Willert C, Mallet C, Foley R, Foster P, Dekaban GA. Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. International Immunology 2012; 24(1):29-41.
75. Ahrens ET, Young WB, Xu H, Pusateri LK. Rapid quantification of inflammation in tissue samples using perfluorocarbon emulsion and fluorine-19 nuclear magnetic resonance. BioTechniques 2011; 50(4):229-234.
76. Tallacchini M, Beloucif S. Regulatory issues in xenotransplantation: recent developments. Current Opinion in Organ Transplantation 2009; 14(2):180-185.
77. Katz R FDA: evidentiary standards for drug development and approval. NeuroRx 2004; 1(3):307-316.
78. Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem cell therapy as an emerging paradigm for stroke (STEPS) II. Stroke 2011; 42(3):825-829.
79. Stem Cell Therapies as an Emerging Paradigm in Stroke P. Stem cell therapies as an emerging paradigm in stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009; 40(2):510-515.
80. Sinden JD, Muir KW. Stem cells in stroke treatment: the promise and the challenges. International Journal of Stroke 2012; 7(5):426-434.
81. Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. European Journal of Clinical Pharmacology 2003; 59(5-6):357-366.
82. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Medicine 2010; 7(3):e1000251.
83. Bernabe RD, van Thiel GJ, Raaijmakers JA, van Delden JJ. The risk-benefit task of research ethics committees: an evaluation of current approaches and the need to incorporate decision studies methods. BMC Medical Ethics 2012; 13:6.
84. Saudek F, Jirak D, Girman P, Herynek V, Dezortova M, Kriz J, Peregrin J, Berkova Z, Zacharovova K, Hajek M. Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. Transplantation 2010; 90(12):1602-1606.
85. Toso C, Vallee JP, Morel P, Ris F, Demuylder-Mischler S, Lepetit-Coiffe M, Marangon N, Saudek F, James Shapiro AM, Bosco D, Berney T. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. American Journal of Transplantation 2008; 8(3):701-706.
86. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, Gray C, Crawford JH, Alam SR, Atkinson AP, Forrest EK, Bienek C, Mills NL, Burdess A, Dhaliwal K, Simpson AJ, Wallace WA, Hill AT, Roddie PH, McKillop G, Connolly TA, Feuerstein GZ, Barclay GR, Turner ML, Newby DE. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circul Cardiovasc Imag 2012; 5(4):509-517.
87. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004; 127(Pt 7):1670-1677.
88. Saleh A, Schroeter M, Ringelstein A, Hartung HP, Siebler M, Modder U, Jander S. Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke 2007; 38(10):2733-2737.
89. Dousset V, Brochet B, Deloire MS, Lagoarde L, Barroso B, Caille JM, Petry KG. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. American Journal of Neuroradiology 2006; 27(5):1000-1005.
90. Yilmaz A, Dengler MA, van der Kuip H, Yildiz H, Rosch S, Klumpp S, Klingel K, Kandolf R, Helluy X, Hiller KH, Jakob PM, Sechtem U. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. European Heart Journal 2012; 34(6):462-475.
91. Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, MacGillivray T, McKillop G, Mirsadraee S, Payne J, Fox KA, Henriksen P, Newby DE, Semple SI. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circul Cardiovasc Imag 2012; 5(5):559-565.
92. Jozwiak S, Habich A, Kotulska K, Sarnowaska A, Kropiwnicki T, Janowski M, Jurkiewicz E, Lukomska B, Kmiec T, Walecki J, Roszkowski M, Litwin M, Oldak T, Boruczowski D, Domanska-Janik K. Intracerebroventricular transplantation of cord blood-derived neural progenitors in a child with severe global brain ischemic injury. Cell Med 2010; 1(2):71-80.
93. Callera F, de Melo CM. Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells' migration into the injured site. Stem Cells Devl 2007; 16(3):461-466.
94. Yilmaz A, Rosch S, Klingel K, Kandolf R, Helluy X, Hiller KH, Jakob PM, Sechtem U. Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction - preliminary results. International Journal of Cardiology 2011; 163(2):175-182.